全文获取类型
收费全文 | 8176篇 |
免费 | 543篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 86篇 |
儿科学 | 183篇 |
妇产科学 | 221篇 |
基础医学 | 1144篇 |
口腔科学 | 410篇 |
临床医学 | 870篇 |
内科学 | 1599篇 |
皮肤病学 | 178篇 |
神经病学 | 1004篇 |
特种医学 | 163篇 |
外科学 | 730篇 |
综合类 | 37篇 |
一般理论 | 9篇 |
预防医学 | 901篇 |
眼科学 | 104篇 |
药学 | 578篇 |
中国医学 | 27篇 |
肿瘤学 | 507篇 |
出版年
2024年 | 8篇 |
2023年 | 125篇 |
2022年 | 224篇 |
2021年 | 419篇 |
2020年 | 246篇 |
2019年 | 332篇 |
2018年 | 353篇 |
2017年 | 287篇 |
2016年 | 277篇 |
2015年 | 333篇 |
2014年 | 449篇 |
2013年 | 518篇 |
2012年 | 819篇 |
2011年 | 788篇 |
2010年 | 418篇 |
2009年 | 336篇 |
2008年 | 507篇 |
2007年 | 525篇 |
2006年 | 429篇 |
2005年 | 375篇 |
2004年 | 278篇 |
2003年 | 231篇 |
2002年 | 230篇 |
2001年 | 37篇 |
2000年 | 25篇 |
1999年 | 32篇 |
1998年 | 20篇 |
1997年 | 16篇 |
1996年 | 13篇 |
1995年 | 7篇 |
1994年 | 6篇 |
1993年 | 11篇 |
1992年 | 11篇 |
1991年 | 9篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1975年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有8751条查询结果,搜索用时 15 毫秒
81.
Developing and Testing of a Software Prototype to Support Diagnostic Reasoning of Nursing Students 下载免费PDF全文
82.
Manuel R. Mazenauer Stole Manov Vanessa M. Galati Philipp Kappeler Jürgen Stohner 《RSC advances》2018,8(6):2872
Correction for ‘Synthetic routes for a variety of halogenated (chiral) acetic acids from diethyl malonate’ by Manuel R. Mazenauer et al., RSC Adv., 2017, 7, 55434–55440.An incorrect email address was provided for affiliation a, the correct version, along with capitalisation of Zürich in affiliation b, is shown below.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers. 相似文献
83.
Masliza Mahmod Nikhil Pal Jennifer Rayner Cameron Holloway Betty Raman Sairia Dass Eylem Levelt Rina Ariga Vanessa Ferreira Rajarshi Banerjee Jurgen E. Schneider Christopher Rodgers Jane M. Francis Theodoros D. Karamitsos Michael Frenneaux Houman Ashrafian Stefan Neubauer Oliver Rider 《Journal of cardiovascular magnetic resonance》2018,20(1):88
Background
Heart failure (HF) is characterized by altered myocardial substrate metabolism which can lead to myocardial triglyceride accumulation (steatosis) and lipotoxicity. However its role in mild HF with preserved ejection fraction (HFpEF) is uncertain. We measured myocardial triglyceride content (MTG) in HFpEF and assessed its relationships with diastolic function and exercise capacity.Methods
Twenty seven HFpEF (clinical features of HF, left ventricular EF >50%, evidence of mild diastolic dysfunction and evidence of exercise limitation as assessed by cardiopulmonary exercise test) and 14 controls underwent 1H-cardiovascular magnetic resonance spectroscopy (1H-CMRS) to measure MTG (lipid/water, %), 31P-CMRS to measure myocardial energetics (phosphocreatine-to-adenosine triphosphate - PCr/ATP) and feature-tracking cardiovascular magnetic resonance (CMR) imaging for diastolic strain rate.Results
When compared to controls, HFpEF had 2.3 fold higher in MTG (1.45?±?0.25% vs. 0.64?±?0.16%, p?=?0.009) and reduced PCr/ATP (1.60?±?0.09 vs. 2.00?±?0.10, p?=?0.005). HFpEF had significantly reduced diastolic strain rate and maximal oxygen consumption (VO2 max), which both correlated significantly with elevated MTG and reduced PCr/ATP. On multivariate analyses, MTG was independently associated with diastolic strain rate while diastolic strain rate was independently associated with VO2 max.Conclusions
Myocardial steatosis is pronounced in mild HFpEF, and is independently associated with impaired diastolic strain rate which is itself related to exercise capacity. Steatosis may adversely affect exercise capacity by indirect effect occurring via impairment in diastolic function. As such, myocardial triglyceride may become a potential therapeutic target to treat the increasing number of patients with HFpEF.84.
Kazimierz O. Wrzeszczynski Vanessa Felice Avinash Abhyankar Lukasz Kozon Heather Geiger Dina Manaa Ferrah London Dino Robinson Xiaolan Fang David Lin Michelle F. Lamendola-Essel Depinder Khaira Esra Dikoglu Anne-Katrin Emde Nicolas Robine Minita Shah Kanika Arora Olca Basturk Vaidehi Jobanputra 《The Journal of molecular diagnostics : JMD》2018,20(6):822-835
85.
86.
Ofir Moreno Todd Butler Vanessa Zann Ashley Willson Pui Leung Alyson Connor 《Clinical therapeutics》2018,40(11):1855-1867
Purpose
ME-401 is a novel selective inhibitor of phosphatidylinositol 3 kinase p110δ, an enzyme often found overexpressed and overactive in B-cell malignancies. The current study was performed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending oral doses of ME-401 in healthy volunteers.Methods
This analysis was an open-label, nonrandomized study in healthy male volunteers. Three sequential groups were dosed. Each group received single doses of ME-401 on two occasions; the doses tested ranged from 10 to 150 mg. Blood was drawn at various time points to analyze plasma concentrations of ME-401 and inhibition of basophil activation, a marker of phosphatidylinositol 3 kinase p110δ inhibition.Findings
Fifteen subjects received a single dose of ME-401 on two occasions. Three adverse events that were considered possibly related to the study drug were reported: one event of pain, one event of headache, and one event of upper abdominal pain. ME-401 exhibited dose proportionality up to 60 mg, and supra-proportional increases in exposure were observed above doses of 60 mg. In addition, there was a dose-proportional increase in the inhibition of basophil activation up to 60 mg. Mean t1/2 ranged from 9.36 to 29.23 hours across the dose range. A 60 mg dose of ME-401 approached 90% inhibition of basophil activation, and thereafter no further increase to the percent inhibition of basophil activation was observed for higher doses. Once-daily dosing of 60 mg ME-401 was forecasted to result in trough plasma levels exceeding the concentration needed for 90% inhibition of basophil activation.Implications
This first-in-human study showed that ME-401 was well tolerated after single doses up to 150 mg. Pharmacologic activity was confirmed after administration of single ascending oral doses of 10 to 150 mg. ME-401 60 mg, administered once daily, was selected as the starting dose for patient studies. ClinicalTrials.gov identifier: NCT02521389. 相似文献87.
88.
89.
90.
Mattijs M. Heemskerk Martin Giera Fatiha el Bouazzaoui Mirjam A. Lips Hanno Pijl Ko Willems van Dijk Vanessa van Harmelen 《Nutrients》2015,7(9):7676-7690
Obese women with type 2 diabetes mellitus (T2DM) have more inflammation in their subcutaneous white adipose tissue (sWAT) than age-and-BMI similar obese women with normal glucose tolerance (NGT). We aimed to investigate whether WAT fatty acids and/or oxylipins are associated with the enhanced inflammatory state in WAT of the T2DM women. Fatty acid profiles were measured in both subcutaneous and visceral adipose tissue (vWAT) of 19 obese women with NGT and 16 age-and-BMI similar women with T2DM. Oxylipin levels were measured in sWAT of all women. Arachidonic acid (AA) and docosahexaenoic acid (DHA) percentages were higher in sWAT, but not vWAT of the T2DM women, and AA correlated positively to the gene expression of macrophage marker CD68. We found tendencies for higher oxylipin concentrations of the 5-LOX leukotrienes in sWAT of T2DM women. Gene expression of the 5-LOX leukotriene biosynthesis pathway was significantly higher in sWAT of T2DM women. In conclusion, AA and DHA content were higher in sWAT of T2DM women and AA correlated to the increased inflammatory state in sWAT. Increased AA content was accompanied by an upregulation of the 5-LOX pathway and seems to have led to an increase in the conversion of AA into proinflammatory leukotrienes in sWAT. 相似文献